X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
ADCOCK INGRAM
Jun-14
GSK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs2,760368-   
Low Rs2,040266-   
Sales per share (Unadj.) Rs339.0109.6-  
Earnings per share (Unadj.) Rs41.4-27.6-  
Cash flow per share (Unadj.) Rs45.9-22.9-  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.986.0-  
Shares outstanding (eoy) m84.70168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.12.9 244.7%   
Avg P/E ratio x57.9-11.5 -504.7%  
P/CF ratio (eoy) x52.3-13.9 -377.3%  
Price / Book Value ratio x9.93.7 268.0%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,28053,502 379.9%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m5,2343,358 155.9%   
Avg. sales/employee Rs ThNM4,307.3-  
Avg. wages/employee Rs ThNM782.2-  
Avg. net profit/employee Rs ThNM-1,085.3-  
INCOME DATA
Net Sales Rs m28,71518,491 155.3%  
Other income Rs m545129 421.2%   
Total revenues Rs m29,26018,621 157.1%   
Gross profit Rs m5,059-3,204 -157.9%  
Depreciation Rs m380798 47.6%   
Interest Rs m2501 0.4%   
Profit before tax Rs m5,222-4,374 -119.4%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892273 692.3%   
Profit after tax Rs m3,508-4,659 -75.3%  
Gross profit margin %17.6-17.3 -101.7%  
Effective tax rate %36.2-6.2 -579.8%   
Net profit margin %12.2-25.2 -48.5%  
BALANCE SHEET DATA
Current assets Rs m21,81513,543 161.1%   
Current liabilities Rs m15,9997,620 210.0%   
Net working cap to sales %20.332.0 63.2%  
Current ratio x1.41.8 76.7%  
Inventory Days Days64111 57.3%  
Debtors Days Days19124 15.1%  
Net fixed assets Rs m12,4757,894 158.0%   
Share capital Rs m84786 986.6%   
"Free" reserves Rs m19,7260-   
Net worth Rs m20,57314,514 141.8%   
Long term debt Rs m65,100 0.1%   
Total assets Rs m39,47527,417 144.0%  
Interest coverage x2,612.0-7.7 -33,780.6%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.70.7 107.9%   
Return on assets %8.9-15.2 -58.6%  
Return on equity %17.1-32.1 -53.1%  
Return on capital %26.2-19.8 -132.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,8650-   
CASH FLOW
From Operations Rs m4,7281,578 299.6%  
From Investments Rs m-1,042-485 215.0%  
From Financial Activity Rs m-3,0664,629 -66.2%  
Net Cashflow Rs m6205,723 10.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.08 Rs / ZAR

Compare GSK PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: SANOFI INDIA  FRESENIUS KABI ONCO.  DR. DATSONS LABS  FDC LTD.  PIRAMAL ENTERPRISES  



Today's Market

Sensex Opens Flat; Capital Goods & Banking Stocks Lag(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is down 1.2%.

Related Views On News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 13, 2018 10:17 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS